ociperlimab,tislelizumab
novartis,beigene
['tislelizumab', 'ociperlimab', 'advantig,105', '$bgne']
$bgne presented robust efficacy data showing orr 57.6% from ph1b advantig-105 trial evaluating ociperlimab + tislelizumab + chemo in her2- st. iv gc/gejc. responses were maintained regardless of pd-l1 tap score #asco2023 # asco23 #cancer #tigit 
Course5i prides itself in enabling #LifeSciences organizations with insights, #analytics and #AI to drive strategic decisions. Enabling better health outcomes.